The Department of Health and Human Services' National Institutes of Health National Institute on Aging has awarded a $830,053.00 firm fixed price delivery order contract to QPS Austria GMBH, a contract research organization, to conduct experimental validation of candidate Alzheimer's disease treatments identified through multi-omics analyses. This delivery order is part of a larger indefinite delivery contract with QPS Austria GMBH to provide these services, with a potential total value...
This federal contract award to Scantox Neuro GMBH, a for-profit organization based in Austria, is for $249,000.00 to conduct tolerability studies of candidate Alzheimer's disease (AD) drugs and evaluate the efficacy of poly(L-lysine succinylated)-hydroxychloroquine (PLS-HCQ) in a transgenic AD mouse model. The award is part of the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) and Experimental Validation of Candidate Alzheimer's Disease Treatments Identified by Multi-Omics Analyses...
<p>The National Institutes of Health National Institute on Aging, within the Department of Health and Human Services, awarded a $638,000 firm fixed price delivery order contract to QPS Austria GmbH. The contract is for experimental validation of candidate Alzheimer's disease treatments identified through multi-omics analyses. The period of performance is from June 1, 2022 through May 31, 2023, with all work to be conducted in Austria by QPS Austria GmbH as the prime contractor.</p>
This is a $249,334 firm fixed-price purchase order awarded by the National Institute on Aging (NIA) to Scantox Neuro GMBH, a for-profit organization based in Austria. The contract supports pharmacodynamic and tolerability studies of candidate Alzheimer's disease (AD) drugs using a transgenic AD mouse model. This work builds on NIA's ongoing efforts under the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) and Experimental Validation of Candidate Alzheimer's Disease Treatments...
This is a firm fixed-price delivery order contract awarded by the National Institute on Aging (NIA), a civilian federal agency, to Scantox Neuro GMBH, a for-profit organization based in Austria. The contract, valued at $858,106.08, is for the experimental validation of candidate Alzheimer's disease treatments identified through multi-omics analyses. This work supports ongoing NIA research initiatives such as the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) and PREVENT-AD studies....
The Department of Health and Human Services' National Institutes of Health National Institute on Aging awarded a $298,624 firm fixed-price purchase order to QPS Austria GmbH to provide phenotypic screening services to identify effective treatments for Alzheimer's disease. The requirement, as outlined in the solicitation, is for the contractor to test approximately 20 FDA-approved drugs that have been nominated as potential treatments in order to determine if exposure is associated with lower...
This is a firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Aging to the National University of Singapore. The $169,830 contract is for testing the efficacy of candidate Alzheimer's disease treatments in rescuing impaired hippocampal synaptic plasticity. This is part of the NIH's Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study, which is testing approximately 20 FDA-approved drugs to...
This is a firm-fixed-price purchase order award to Alamar Biosciences, Inc. by the National Institute on Aging (NIA), a civilian agency, for $247,000.00. The contract is for providing proteomic analysis services, including the NULISAseq CNS Disease Panel 120 assay, next-generation sequencing, and bioinformatic support for 1,118 plasma samples. The purpose is to identify biomarkers that can be used to classify and stage Alzheimer's disease. This award is not associated with a set-aside and is the...
This is a firm-fixed price purchase order awarded by the National Institute on Aging, a civilian federal agency, to the National University of Singapore (NUS) for $37,362.60. The contract is for testing the efficacy of novel candidate Alzheimer's disease drugs in rescuing impaired hippocampal synaptic plasticity in the APP/PS1 transgenic mouse model. The award does not utilize any set-aside designations, reflecting NUS's competitive capabilities as an international research institution. NUS...
This is a $1,485,008.40, firm-fixed-price contract awarded by the National Institute on Drug Abuse (NIDA), on behalf of the National Institute of Neurological Disorders and Stroke (NINDS), to Curia Global Inc. (doing business as Amri). The contract is for the non-GMP synthesis of up to 100 compounds in 2-10 milligram quantities to support a medicinal chemistry discovery program focused on identifying molecules that bind the KIAA0203 protein, which could potentially lead to the development of a...
This is a $199,812 firm fixed price purchase order awarded by the National Institutes of Health's (NIH) National Institute on Aging (NIA) to QPS Austria GMBH, a contract research organization. The contract is for in vivo efficacy studies of a candidate Alzheimer's treatment in a transgenic mouse model. This award is part of the NIA's Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study, which aims to identify FDA-approved drugs that may be repurposed as disease-modifying Alzheimer's treatments. The award has a period of performance from September 30, 2021 to September 29, 2022. There is no set aside designation on this contract.